Prosecution Insights
Last updated: April 19, 2026
Application No. 18/011,248

COATING COMPOSITION AND LAMINATE

Final Rejection §103
Filed
Dec 19, 2022
Examiner
SHAH, SAMIR
Art Unit
1787
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Mitsui Chemicals Inc.
OA Round
2 (Final)
36%
Grant Probability
At Risk
3-4
OA Rounds
4y 9m
To Grant
69%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allow Rate
182 granted / 513 resolved
-29.5% vs TC avg
Strong +33% interview lift
Without
With
+33.3%
Interview Lift
resolved cases with interview
Typical timeline
4y 9m
Avg Prosecution
59 currently pending
Career history
572
Total Applications
across all art units

Statute-Specific Performance

§103
53.8%
+13.8% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
22.0%
-18.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 513 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-3 and 5-11 is/are rejected under 35 U.S.C. 103 as being unpatentable over Tagami (JP 2013-188871). Regarding claim 1 and 5, Tagami discloses primer layer, i.e. a coating, comprising isocyanate compound, i.e. polyisocyanate component, acrylic polyol (0006, 0010, 0024), and methyl acetate, i.e. organic solvent containing alkyl ester, (0038) wherein the polyisocyante component includes an aromatic ring containing isocyanate (0030) and acrylic polyol is a polymer of a monomer composition containing a hydroxyl group containing polymerizable monomer and a carboxyl group containing polymerizable monomer (0028). Given that Tagami does not disclose acrylonitrile in the coating layer, it is clear that the coating of Tagami is free of acrylonitrile. Tagami is silent regarding equivalent ratio of isocyanate group of the polyisocyanate component to hydroxyl group of polyol component and a mass ratio of carboxyl containing monomer to the hydroxyl group containing monomer. Since the instant specification is silent to unexpected results, the specific equivalent ratio isocyanate groups of the polyisocyanate component to hydroxyl group of polyol component and a mass ratio of carboxyl containing monomer to the hydroxyl group containing monomer is not considered to confer patentability to the claims. As the film quality and adhesion that can be modified (0034-0037), among others, by adjusting the amounts of polyisocyanate component and acrylic polyol, the precise amounts would have been considered a result effective variable by one having ordinary skill in the art at the time the invention was made. As such, without showing unexpected results, the claimed amounts cannot be considered critical. Accordingly, one of ordinary skill in the art at the time the invention was made would have optimized, by routine experimentation, the amounts of each component in the coating to obtain the desired film quality and adhesion (In re Boesch, 617 F.2d. 272, 205 USPQ 215 (CCPA 1980)), since it has been held that where the general conditions of the claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. (In re Aller, 105 USPQ 223). Regarding claim 2, Tagami discloses the coating composition of claim 1, wherein the aromatic ring containing isocyanate includes tetramethylxylylene diisocyanate (0030). Regarding claim 3, Tagami discloses the coating composition of claim 1, wherein the monomer composition includes styrene monomer, i.e. an aromatic vinyl monomer, (0028). Regarding claim 6, Tagami discloses the coating composition of claim 1, wherein a content ratio of the carboxyl group containing monomer is 5 parts by mass with respect to 100 parts by mass of the total amount of the monomer composition (table 1, example 11). Regarding claim 7, Tagami discloses the coating composition of claim 1, wherein given that Tagami discloses the same acrylic polyol as claimed in present claim, it is clear that the acrylic polyol of Tagami would inherently have the same properties as present claim. Regarding claim 9, Tagami discloses a laminate comprising a resin layer 32, an inorganic thin film layer 13 disposed on one side in the thickness direction of the resin film, a primer layer 12 made of composition of claim 1, i.e. cured product of polyisocyanate component and acrylic polyol (polyurethane), (0032, 0038) disposed on one side in the thickness direction of the inorganic thin film layer, an adhesive layer 31 disposed on one side in the thickness direction of the polyurethane layer, and a heat sealable film 32 disposed on one side in the thickness direction of the adhesive layer (0052, 0069, fig. 3). Regarding claim 10, Tagami discloses the laminate of claim 9, wherein the organic thin film layer includes silicon oxide (0042). Regarding claim 11, Tagami discloses the laminate of claim 9, wherein the resin film includes polyethylene resin, i.e. polyolefin resin, (0052-0053). Response to Arguments Applicant's arguments filed 09/08/2025 have been fully considered but they are not persuasive. Applicant points to examples in specification and argues the criticality of using the equivalent ratio of polyisocyanate component to hydroxyl groups of the polyol. However, the data is not persuasive given that the data is not commensurate in scope with the scope of the present claims. The examples disclose specific type and amounts of polyisocyanate component, acrylic polyol and organic solvent while the present claim broadly recites any type and amount of polyisocyanate component, acrylic polyol and organic solvent. As set forth in MPEP 716.02(d), whether unexpected results are the result of unexpectedly improved results or a property not taught by the prior art, “objective evidence of nonobviousness must be commensurate in scope with the claims which the evidence is offered to support”. In other words, the showing of unexpected results must be reviewed to see if the results occurred over the entire claimed range, In re Clemens, 622 F.2d 1029, 1036, 206 USPQ 289, 296 (CCPA 1980). Applicants have not provided data to show that the unexpected results do in fact occur over the entire claimed range. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAMIR SHAH whose telephone number is (571)270-1143. The examiner can normally be reached 8:00am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Callie Shosho can be reached at 571-272-1123. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAMIR SHAH/Primary Examiner, Art Unit 1787
Read full office action

Prosecution Timeline

Dec 19, 2022
Application Filed
Jun 06, 2025
Non-Final Rejection — §103
Sep 08, 2025
Response Filed
Oct 10, 2025
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600542
Multilayer Structure and Packaging Material Comprising Same
2y 5m to grant Granted Apr 14, 2026
Patent 12589555
DIRECT APPLICATION OF THERMOSETTING COMPOSITE SURFACING FILMS TO UV-TREATED THERMOPLASTIC SURFACES AND RELATED COMPOSITE STRUCTURES
2y 5m to grant Granted Mar 31, 2026
Patent 12583164
MULTILAYER ARTICLES AND METHODS OF MAKING
2y 5m to grant Granted Mar 24, 2026
Patent 12577358
GAS BARRIER FILM AND METHOD OF PRODUCING THE SAME
2y 5m to grant Granted Mar 17, 2026
Patent 12577432
ORGANOSILICON COMPOUND, PRODUCTION METHOD THEREFOR, AND CURABLE COMPOSITION
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
36%
Grant Probability
69%
With Interview (+33.3%)
4y 9m
Median Time to Grant
Moderate
PTA Risk
Based on 513 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month